| Literature DB >> 34598718 |
Lewis Winning1, Fionnuala T Lundy2, Bronagh Blackwood2, Daniel F McAuley2, Ikhlas El Karim3.
Abstract
BACKGROUND: The link between oral bacteria and respiratory infections is well documented. Dental plaque has the potential to be colonized by respiratory pathogens and this, together with microaspiration of oral bacteria, can lead to pneumonia particularly in the elderly and critically ill. The provision of adequate oral care is therefore essential for the maintenance of good oral health and the prevention of respiratory complications. MAIN BODY: Numerous oral care practices are utilised for intubated patients, with a clear lack of consensus on the best approach for oral care. This narrative review aims to explore the oral-lung connection and discuss in detail current oral care practices to identify shortcomings and offer suggestions for future research. The importance of adequate oral care has been recognised in guideline interventions for the prevention of pneumonia, but practices differ and controversy exists particularly regarding the use of chlorhexidine. The oral health assessment is also an important but often overlooked element of oral care that needs to be considered. Oral care plans should ideally be implemented on the basis of an individual oral health assessment. An oral health assessment prior to provision of oral care should identify patient needs and facilitate targeted oral care interventions.Entities:
Keywords: Chlorhexidine; Oral bacteria; Oral health; Pneumonia; VAP
Mesh:
Year: 2021 PMID: 34598718 PMCID: PMC8485109 DOI: 10.1186/s13054-021-03765-5
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Oral health assessment tools commonly used in ICUs
| Tool | Content | Measurement | Validation | Other |
|---|---|---|---|---|
Beck Oral Assessment Score (BOAS) Beck [ | lips, tongue and mucosa, gingiva, teeth and saliva | 5 items each with a four-point scale 1–4 Max score 20 | No | Developed for assessment of stomatitis post chemotherapy and adopted with modification for ICU |
Bedside oral exam (BOE) Prendergast et al. [ | Lips, tongue, saliva, mucous membranes, gingiva, teeth and odour | 8 Items each with a three-point scale 1–3 Max score 24 | Yes | Modified from the Oral Assessment Guide (OAG) developed for assessment of mucositis post radiation therapy and adopted with modification for ICU |
Mucosal Plaque Score (MPS) Henriksen et al. [ | Plaque Mucosa | 1–4 Point scale for each item Max score 8 | No | Developed to assess oral care in the elderly |
The BRUSHED Assessment Model Hayes and Jones [ | Bleeding, redness, ulceration, saliva, halitosis, external factors, and debris | Mnemonic to aid nursing staff in detecting clinical signs of impaired oral health | No | Its use in ICU is not well documented |
Summary of systemic reviews findings on the effect of chlorhexidine used in ICUs
| Study | Intervention/comparisons | Outcomes | Relative effect | Number of participants | Grade |
|---|---|---|---|---|---|
Zhao et al. [ China | CHX (mouth rinse or gel) versus placebo/usual care | VAP | CHX reduced VAP: RR 0.67 (95% CI 0.47–0.97) | 1206 (13 studies) | ⨁⨁⨁◯ Moderate |
| Mortality | No difference RR 1.03 (95% CI 0.80 to1.33) | 944 (9 studies) | ⨁⨁⨁◯ Moderate | ||
| ICU stay | No difference 0.89 (95%CI-3.59–1.82) | 627 (5 studies) | ⨁⨁◯◯ Low | ||
Silvestri et al. [ Italy | CHX (0.12–0.2% solution or gel) versus placebo, usual care | Mortality | No difference OR: 0.69 (95% CI 0.31–1.53)a | 1655 (5 studies) | Not reported |
| Bloodstream infection | No difference OR: 0.74; 95% CI 0.37–1.50 | ||||
Hua et al. [ China | CHX (mouth rinse or gel) versus placebo/usual care | VAP | CHX reduced VAP RR 0.75 (95% CI 0.62–0.91) | 2451(18 studies) | ⨁⨁⨁⨁ High |
| Mortality | No difference RR 1.09 (95% CI 0.96–1.23) | 2014(14 studies) | ⨁⨁⨁◯ Moderate | ||
| ICU stay | No difference 0.21 (95%CI -1.48 -1.89) | 833 (6 studies) | ⨁⨁⨁◯ Moderate | ||
Villar et al. [ Brazil | CHX (0.12–2% solution, gel or foam) versus placebo or usual care | VAP | No difference with 0.1 and 0.2% 2% CHX reduced VAP RR:0.53 (95% CI 0.31–0.91) | 1640 (13 studies) | Not reported |
Klompas et al. [ USA | Interventions: CHX (0.12–2% solution, or gel) versus placebo/usualcare | VAP | CHX reduced VAP RR, 0.56 (95% CI, 0.41–0.77) in CS No significant difference for NCS RR, 0.88 (95% CI, 0.66–1.16) | 1868 (3 studies) | Not reported |
| Mortality | No difference: CS RR, 0.88 (95% CI, 0.25–2.14) NCS RR, 1.13, 95% CI, 0.99–1.29 | 1762 (13 studies) | Not reported | ||
Price et al. [ UK | SDD, SOD and topical oropharyngeal CHX versus usual care | Mortality | SDD reduced mortality OR 0.73 (95%CI 0.64–0.84) | 7839 (15 studies) | Not reported |
SOD reduce mortality OR 0.85 (95%CI 0.74–0.97) | 4276 (4 studies) | Not reported | |||
CHX increased mortality OR 1.25 9% CI 1.05–1.50 | 2618 (11 studies) | Not reported |
CS, cardia surgery; NCS, non cardiac surgery; CHX, chlorhexidine; SDD, selective digestive decontamination; SOD, selective oropharyngeal decontamination; OR, odds ratio; RR, risk ratio
aCombined summary of interventions versus control